… (PETs) share numerous features with gastrointestinal neuroendocrine (carcinoid) tumors.
Targets of novel therapeutic strategies previously assessed in carcinoid tumors were analyzed …

… molecular markers for endocrine progression that could be useful as prognostic markers or
therapeutic … may facilitate the development of novel therapies and molecular screening tests. …

… The overexpression of the src-like kinase LCK (p56 LCK ) is particularly relevant, and offers
a potential novel therapeutic target for PETs. LCK is an src-like non-receptor protein tyrosine …

… Over the years, technological progress and knowledge increase have driven an evolving
pathological classification of pituitary endocrine tumours, from a tinctorial classification to an …

… Progress in both areas should advance preclinical assays of novel therapeutics. In that
regard, more progress in establishing patient-derived spheroid, organoid, and xenograft models …

… Over the past few years, knowledge regarding the molecular pathology of sporadic pancreatic
neuroendocrine tumors (PNETs) has increased substantially, and a number of targeted …

… A similar use of molecular markers is in patients with well … tumor that would be responsive
to platinum-based therapies. … differentiated tumors (panNECs) will guide a change of therapy …

… Additionally, targeting of the cellular surface markers CD47 and CD73 decreased the tumor
… of novel therapeutic targets for PanNETs, and this review details the molecular pathways …

… be used to study liver metastasis and to test novel therapeutic strategies (74,75). The limitations
… Lastly, improving detection of aggressive tumors by evaluating novel molecular markers …

… There is also hope that the insights gained from such molecular studies may suggest novel
therapeutic approaches, which are also urgently required for PanNEN patients, especially in …